BioSpace: Icosavax's Nanoparticle VLP-based Vaccine Offers First-in-Class Solution for RSV

BioSpace reporter Gail Dutton reports on Icosavax's computationally designed virus-like particle (VLP) vaccine platform as a potential first-in-class vaccine for respiratory syncytial virus (RSV).

To read the article, click here.

Icosavax, Inc.

1616 Eastlake Avenue E. Suite 208 
Seattle, WA 98102

  • White Twitter Icon
  • White Facebook Icon
  • White LinkedIn Icon

© 2020 Icosavax, Inc. All rights reserved.